ir-world-logo irw-world-logo-bogen
facebook-logo youtubelogo twitterlogo googlepluslogo rsslogo linkedinlogo pinterestlogo xinglong
Sirona Biochem Corp. 22.05.2019

Sirona Biochem Hires Contract Research Organization for Manufacturing Process Optimization for TFC-1067


Vancouver, British ColumbiaMay 22, 2019 Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) is pleased to announce it has commissioned Contract Research Organization (CRO) Roowin ( to develop the final chemical process required for large scale manufacturing of TFC-1067. This is another important step in the commercialization of Sirona’s novel skin lightening agent.


Sirona anticipates the need for multiple kilogram production of TFC-1067 in the short term and is therefore taking this necessary intermediate step. Sirona will then proceed to manufacture an inventory of TFC-1067 of up to 20 kilograms to be ready for anticipated orders. Due to the high potency of the compound, each kilogram will supply Sirona’s active skin lightening ingredient to produce ten thousand consumer size (fifty milliliters) containers of finished product.


“The chemistry of TFChem (Sirona’s subsidiary) is unique and our science team has an excellent understanding of this chemistry. We have already successfully worked on production of TFC-1067 at the kilogram scale”, reports Patrice Rool, CEO of Roowin. Our scientists will collaborate with TFChem to develop the most efficient final process to manufacture TFC-1067. We are very excited to be a part of the ongoing development of this innovative skin lightener.


Roowin’s expertise in manufacturing process development will move TFC-1067 closer to final commercialization. In addition, our scientists at TFChem have developed new chemistry that will further improve manufacturing efficiencies and lower cost of goods, Dr. Verrico concluded.  The new manufacturing process for TFC-1067 we anticipate will be used at manufacturing sites globally down the road. Roowin has extensive experience with our chemistry and we are excited to be working together again.”


About Roowin


Roowin is a privately-owned Contract Research Organization (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value-added fine chemistry, Roowin offers a large range of chemical services. Roowin supports customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches, about 20 kilograms.


Roowin is accredited ISO 9001. Roowin’s facilities include cGMP facilities: Kilo-laboratory / Pilot plant. Roowin can accompany its customers from early lead optimization through scale-up and small-scale GMP synthesis up to medium scale GMP manufacturing.


For more information, please visit


About Sirona Biochem Corp.


Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.


Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


For more information regarding this press release, please contact:


Christopher Hopton, CFO

Sirona Biochem Corp.



Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

> Sirona Biochem Corp., weitere Meldungen...